Figure 1.

Asymmetric arginine dimethylation is highly abundant in postmitotic spinal cord MNs. A, Immunoblot analysis of FUS, methylated FUS, symmetric (SYM11) and asymmetric (ADMA) arginine dimethylated protein levels in ESCs versus spinal cord samples derived from 2-week-old (2w) to 6-month-old (6m) mice. Representative result of at least three independent immunoblot analyses and its quantification are shown. Note that FUS in ESCs show slightly different molecular weight. B, Coimmunostaining of mouse spinal cord cross sections derived from 2-week-old, 1-month-old, and 3-month-old animal for ADMA-containing proteins and GFAP (astrocyte marker). Magnification of a region marked by yellow star on the section of the 1-month-old sample is shown below the panel. Representative results of at least three independent analyses and their quantification are shown. Scale bar, 25 μm. C, Coimmunostaining of spinal cord cross sections derived from 6-month-old mouse for ADMA-containing proteins, methylated FUS (Met FUS), and ChAT (MN marker). Representative results of at least three independent analyses are shown. Scale bar, 25 μm. D, Immunoblot analysis of ADMA levels in G93A SOD1 transgenic (S) and control (N) mice (n = 4 in each group). Onset ages of the disease were determined as the time when the animals reached peak body weight and the end stage of the disease were determined when the animals could not right themselves within 10 s when placed on their side (typically 12–15 weeks). Data are presented as mean ± SEM. **p ≤ 0.01 (Student's t-test).